Drug-induced movement disorders.
This review covers the major categories of movement disorders secondary to the use of antipsychotic drugs and other pharmacologic agents that interfere with dopaminergic transmission at the basal ganglionic level. In the past year new syndromes were reported, old concepts were either challenged or supported by recent studies, and significant contributions were made in unraveling the complex pathophysiology of these disorders.
Gershanik
O S
OS
Seccion Enfermedades Extrapiramidales, Centro Neurologico-Hospital Frances, Buenos Aires, Argentina.
D017109:Akathisia, Drug-Induced / Q000175:diagnosis / Q000503:physiopathology; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004298:Dopamine / Q000502:physiology; D018492:Dopamine Antagonists; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000503:physiopathology*; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000503:physiopathology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000175:diagnosis / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000187:drug effects* / Q000502:physiology; D012307:Risk Factors; D009435:Synaptic Transmission / Q000187:drug effects* / Q000502:physiology; D013577:Syndrome
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D004298:Dopamine